{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:50:25Z","timestamp":1756191025286},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,25]]},"DOI":"10.7759\/cureus.59019","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T21:16:01Z","timestamp":1714079761000},"source":"Crossref","is-referenced-by-count":1,"title":["Adalimumab (ADA) in Pediatric Non-infectious Uveitis: An Observational Study"],"prefix":"10.7759","author":[{"given":"Rihab A","family":"Ghanma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Steeples","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasa","family":"Pockar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Chieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2019.1642080","article-title":"The effectiveness of adalimumab treatment for non-infectious uveitis","volume":"42","author":"Hasegawa E","year":"2019","unstructured":"Hasegawa E, Takeda A, Yawata N, Sonoda KH. The effectiveness of adalimumab treatment for non-infectious uveitis. Immunol Med. 2019, 42:79-83. 10.1080\/25785826.2019.1642080","journal-title":"Immunol Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1288097","article-title":"Adalimumab for the treatment of uveitis","volume":"13","author":"LaMattina KC","year":"2017","unstructured":"LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017, 13:181-188. 10.1080\/1744666X.2017.1288097","journal-title":"Expert Rev Clin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe GJ","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, et al.. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016, 375:932-943. 10.1056\/NEJMoa1509852","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen QD","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, et al.. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016, 388:1183-1192. 10.1016\/S0140-6736(16)31339-3","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan AV","year":"2017","unstructured":"Ramanan AV, Dick AD, Jones AP, et al.. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017, 376:1637-1646. 10.1056\/NEJMoa1614160","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3310\/hta23150","article-title":"Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT","volume":"23","author":"Ramanan AV","year":"2019","unstructured":"Ramanan AV, Dick AD, Jones AP, et al.. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technol Assess. 2019, 23:10.3310\/hta23150","journal-title":"Health Technol Assess"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00142-4","article-title":"Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study","volume":"6","author":"Croft NM","year":"2021","unstructured":"Croft NM, Faubion WA Jr, Kugathasan S, et al.. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2021, 6:616-627. 10.1016\/S2468-1253(21)00142-4","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31190-X","article-title":"Adalimumab in paediatric psoriasis","volume":"1","author":"Kivelevitch D","year":"2017","unstructured":"Kivelevitch D, Menter A. Adalimumab in paediatric psoriasis. Lancet. 2017, 1:5-6. 10.1016\/S0140-6736(17)31190-X","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-019-0181-z","article-title":"Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis","volume":"9","author":"Ho M","year":"2019","unstructured":"Ho M, Chen LJ, Sin HP, et al.. Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet's disease-related uveitis. J Ophthalmic Inflamm Infect. 2019, 9:14. 10.1186\/s12348-019-0181-z","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler EB","year":"2018","unstructured":"Suhler EB, Ad\u00e1n A, Br\u00e9zin AP, et al.. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018, 125:1075-1087. 10.1016\/j.ophtha.2017.12.039","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.10.036","article-title":"Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"128","author":"Suhler EB","year":"2021","unstructured":"Suhler EB, Jaffe GJ, Fortin E, et al.. Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2021, 128:899-909. 10.1016\/j.ophtha.2020.10.036","journal-title":"Ophthalmology"},{"key":"ref12","article-title":"Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis","volume":"35","author":"Leinonen ST","year":"2017","unstructured":"Leinonen ST, Aalto K, Kotaniemi KM, et al.. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol. 2017, 35:1043-1046.","journal-title":"Clin Exp Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas S","year":"2013","unstructured":"Garc\u00eas S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013, 72:1947-1955. 10.1136\/annrheumdis-2012-202220","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes212","article-title":"Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study","volume":"51","author":"Sen ES","year":"2012","unstructured":"Sen ES, Sharma S, Hinchcliffe A, Dick AD, Ramanan AV. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study. Rheumatology (Oxford). 2012, 51:2199-2203. 10.1093\/rheumatology\/kes212","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-019-0333-6","article-title":"Early administration of adalimumab for paediatric uveitis due to Beh\u00e7et's disease","volume":"17","author":"Hiyama T","year":"2019","unstructured":"Hiyama T, Harada Y, Doi T, Kiuchi Y. Early administration of adalimumab for paediatric uveitis due to Beh\u00e7et's disease. Pediatr Rheumatol Online J. 2019, 17:29. 10.1186\/s12969-019-0333-6","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref16","unstructured":"Clinical Commissioning Policy. Adalimumab (Humira) and Infliximab (Remicade) as Anti-TNF Alpha Treatment Options for Paediatric Patients with Severe Refractory Uveitis Reference:  NHS England D12\/P\/a. (2022). https:\/\/www.engage.england.nhs.uk\/consultation\/specialised-services-consultation\/user_uploads\/uveitis-paediatrics-pol...."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2015.12.006","article-title":"Treatment of pediatric uveitis with adalimumab: the MERSI experience","volume":"20","author":"Castiblanco C","year":"2016","unstructured":"Castiblanco C, Meese H, Foster CS. Treatment of pediatric uveitis with adalimumab: the MERSI experience. J AAPOS. 2016, 20:145-147. 10.1016\/j.jaapos.2015.12.006","journal-title":"J AAPOS"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15012","article-title":"Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis","volume":"100","author":"Kouwenberg CV","year":"2022","unstructured":"Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis. Acta Ophthalmol. 2022, 100:e994-e1001. 10.1111\/aos.15012","journal-title":"Acta Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/149235-adalimumab-ada-in-pediatric-non-infectious-uveitis-an-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T21:16:05Z","timestamp":1714079765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/149235-adalimumab-ada-in-pediatric-non-infectious-uveitis-an-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.59019","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}